Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ViaNOx-H
- Development stage
- Unknown
- Lead developer
- Loma Linda University
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
ViaNOx-H is a topical gaseous nitric oxide treatment being developed by Loma Linda University for the management of chronic colonized cutaneous ulcers, specifically those in the lower extremities lasting longer than 8 weeks due to diabetes or venous stasis disease. The therapy involves the topical application of gaseous nitric oxide at concentrations of 8 to 10 parts per million for 8 hours daily over a two-week course. Its primary therapeutic objective is to eradicate the microbial bio-burden and disrupt biofilms within non-healing wounds, thereby promoting a reduction in wound size and facilitating the healing process.
- Other names
- gaseous nitric oxideNitric Oxide
Beyond the preview
Go deeper on ViaNOx-H.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ViaNOx-H.